Glioblastoma TCGA Mesenchymal and IGS 23 Tumors are Identifiable by IHC and have an Immune-phenotype Indicating a Potential Benefit from Immunotherapy.
Cristina CarratoFrancesc AlamedaAnna Esteve-CodinaEstela Pineda LosadaOriol ArpíMaria Martinez-GarcíaMar MalloMarta GutRaquel Lopez-MartosSonia Del BarcoTeresa RibaltaJaume CapelladesJosep PuigOscar GallegoCarlos MesiaAna Maria Muñoz-MarmolIvan ArchillaMontserrat ArumíJulie Marie BlancBeatriz BellosilloSilvia MenendezAnna EsteveSilvia BaguéAinhoa HernandezJordi Craven-BartleRafael FuentesNoemí VidalIban AldecoaNuria de la IglesiaCarmen BalanaPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2020)
There is a subset of tumors, frequently classified as mesenchymal or IGS cluster 23, that may be identified with IHC and could well be optimal candidates for immunotherapy.